"Botulinum Toxins, Type A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.
| Descriptor ID |
D019274
|
| MeSH Number(s) |
D08.811.277.656.300.480.153.100 D08.811.277.656.675.374.153.100 D12.776.097.156.100 D23.946.123.179.050
|
| Concept/Terms |
Botulinum Toxins, Type A- Botulinum Toxins, Type A
- Botulinum Neurotoxin A
- Neurotoxin A, Botulinum
- Clostridium botulinum A Toxin
- Clostridium Botulinum Toxin Type A
- Botulinum A Toxin
- Toxin, Botulinum A
- Botulinum Toxin Type A
|
Below are MeSH descriptors whose meaning is more general than "Botulinum Toxins, Type A".
Below are MeSH descriptors whose meaning is more specific than "Botulinum Toxins, Type A".
This graph shows the total number of publications written about "Botulinum Toxins, Type A" by people in this website by year, and whether "Botulinum Toxins, Type A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Botulinum Toxins, Type A" by people in Profiles.
-
Kopcsay KS, Marczak TD, Jeppson PC, Cameron AP, Khavari R, Tefera E, Gutman RE. Treatment of refractory overactive bladder with OnabotulinumtoxinA vs PTNS: TROOP trial. Int Urogynecol J. 2022 04; 33(4):851-860.
-
Chiu SY, Patel B, Burns MR, Legacy J, Wagle Shukla A, Ramirez-Zamora A, Deeb W, Malaty IA. High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
-
Weller JL, Comeau D, Otis JAD. Myofascial Pain. Semin Neurol. 2018 12; 38(6):640-643.
-
Mahmoud BH, Ozog D, Burnett C, Cohen JL. Prospective Randomized Split-Face Comparative Study Between Topical Botulinum Toxin A Surface Application and Local Injection for Crow's Feet. Dermatol Surg. 2016 Apr; 42(4):554-6.
-
Hastings-Ison T, Blackburn C, Rawicki B, Fahey M, Simpson P, Baker R, Graham K. Injection frequency of botulinum toxin A for spastic equinus: a randomized clinical trial. Dev Med Child Neurol. 2016 Jul; 58(7):750-7.
-
Mahmoud BH, Burnett C, Ozog D. Prospective randomized controlled study to determine the effect of topical application of botulinum toxin A for crow's feet after treatment with ablative fractional CO2 laser. Dermatol Surg. 2015 Jan; 41 Suppl 1:S75-81.
-
Ellsworth P, Travis M. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Urol Nurs. 2014 Jul-Aug; 34(4):165-71.
-
Ellsworth PI. The pharmacologic management of idiopathic overactive bladder in primary care. J Fam Pract. 2014 Feb; 63(2 Suppl):S38-45.
-
Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013 Sep-Oct; 19(5):288-92.
-
Wilkenfeld AJ. Review of electrical stimulation, botulinum toxin, and their combination for spastic drop foot. J Rehabil Res Dev. 2013; 50(3):315-26.